Aurobindo hit with US FDA Form 483 for cephalosporin plant

By Gareth Macdonald

- Last updated on GMT

Aurobindo hit with US FDA Form 483 for cephalosporin plant

Related tags Food and drug administration Us food and drug administration

Aurobindo Pharma Limited has received a Form 483 detailing two problems identified by US FDA inspectors who visited its Unit VI facility in in Chitkul Village, Andhra Pradesh, India.

The first issues raised by the US Food and Drug Administration (FDA) is that Aurobindo does not have written procedures or controls to assure the strength, quality, purity or even identity of drug products made at the facility.

The US agency also said it was is concerned that Aurobindo has not established control procedures to assess the performance of manufacturing processes that have the potential to cause variability in finished drug products.

The audit took place between August 28 and September according to a copy of the document obtained by in-Pharmatechnologist.com.

Unit VI manufactures oral and liquid formulations of cephalosporin antibiotics for multiple markets.

The site has been the subject of US FDA criticism before, notably in 2011​ when the agency issued Aurobindo with a warning letter and imposed an import ban.

The site successfully passed an FDA inspection in September of the following year and – in March 2013 – the import alert was lifted. At the time Aurobindo said the decision paved “the way for resumption of exports of 9 products to the US market​.”

Aurobindo did not respond to a request for comment about the new Form 483.

Related news

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Products

View more

Webinars